Nov 5 (Reuters) - Gentium S.p.A. (GENT.O: Quote, Profile, Research) said it plans to amend the protocol for its late-stage trial of cancer drug Defibrotide with the main goal for the study to change from survival at 100 days to complete response.
Nov 5 (Reuters) - Gentium S.p.A. (GENT.O: Quote, Profile, Research) said it plans to amend the protocol for its late-stage trial of cancer drug Defibrotide with the main goal for the study to change from survival at 100 days to complete response.
